Published in Liver Transpl on April 01, 2010
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol (2013) 0.92
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology (2016) 0.82
Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World J Hepatol (2015) 0.82
Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand? World J Gastroenterol (2014) 0.81
Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today (2016) 0.81
Bi-directional roles of IRF-1 on autophagy diminish its prognostic value as compared with Ki67 in liver transplantation for hepatocellular carcinoma. Oncotarget (2016) 0.77
Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol (2016) 0.76
Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma (2016) 0.75
The role of (90)Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review. Clin Transl Imaging (2016) 0.75
Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome. ISRN Hepatol (2014) 0.75
Liver-allocation policies for patients affected by HCC in Europe. Curr Transplant Rep (2016) 0.75
Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol (2017) 0.75
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 8.20
Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 5.64
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst (2011) 3.51
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61
The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr Blood Cancer (2013) 2.23
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18
Results of a stepwise approach to extrahepatic portal vein obstruction in children. J Pediatr Gastroenterol Nutr (2013) 2.10
Adiponectin and hypertension in normal-weight and obese children. Am J Hypertens (2012) 2.09
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood (2013) 1.91
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol (2009) 1.86
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
Carotid plaque echolucency increases the risk of stroke in carotid stenting: the Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation (2004) 1.82
Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology (2003) 1.79
Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells. Hepatology (2002) 1.79
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet (2012) 1.66
Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology (2013) 1.65
Maternal perception of excess weight in children: a survey conducted by paediatricians in the province of Milan. Acta Paediatr (2005) 1.63
Association between serum values of C-reactive protein and cytokine production in whole blood of patients with type 2 diabetes. Clin Sci (Lond) (2007) 1.63
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol (2010) 1.62
Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion. Gastroenterology (2007) 1.59
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58
Feasibility and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in children. J Pediatr Gastroenterol Nutr (2012) 1.55
Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer (2010) 1.54
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Nutritional status of children during treatment for acute lymphoblastic leukemia in Guatemala. Pediatr Blood Cancer (2012) 1.51
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis (2008) 1.46
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst (2014) 1.46
[A set of indicators to monitor the adherence to the guidelines for the diagnosis and treatment of breast cancer]. Epidemiol Prev (2014) 1.44
Feasibility and limits of split liver transplantation from pediatric donors: an italian multicenter experience. Ann Surg (2006) 1.43
Maternal polymorphisms for methyltetrahydrofolate reductase and methionine synthetase reductase and risk of children with Down syndrome. Am J Obstet Gynecol (2009) 1.42
"The city of Hepar": rituals, gastronomy, and politics at the origins of the modern names for the liver. J Hepatol (2011) 1.42
The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. Blood (2010) 1.40
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica (2005) 1.40
Emerging roles of Notch signaling in liver disease. Hepatology (2014) 1.39
Benefits of cutting balloon before stenting. J Invasive Cardiol (2003) 1.38
Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood (2010) 1.37
Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology (2007) 1.34
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology (2010) 1.31
Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: Assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl (2005) 1.30
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology (2009) 1.29
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). Am J Cardiol (2010) 1.27
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant (2005) 1.23
Improving outcomes for children with cancer in low-income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO)-Part I. Pediatr Blood Cancer (2007) 1.22
Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res (2006) 1.20
Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl (2009) 1.18
Deregulation of microRNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders. J Biol Chem (2011) 1.17
What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica (2013) 1.14
How to tackle the avalanche of chronic kidney disease in sub-Saharan Africa: the situation in the Democratic Republic of Congo as an example. Nephrol Dial Transplant (2006) 1.13
New policies to address the global burden of childhood cancers. Lancet Oncol (2013) 1.12
Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease. Am J Pathol (2008) 1.12
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica (2013) 1.11
Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output. Hepatology (2011) 1.11
Epithelial-mesenchymal interactions in biliary diseases. Semin Liver Dis (2011) 1.11
Usefulness of waist circumference for the identification of childhood hypertension. J Hypertens (2008) 1.10
Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology (2012) 1.09
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol (2008) 1.09
Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Qual Life Res (2012) 1.07
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology (2011) 1.07
Serum uric acid and blood pressure in children at cardiovascular risk. Pediatrics (2013) 1.07
Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat (2012) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
The bioethics agenda and the Bush second term. New Atlantis (2005) 1.06
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group. Br J Haematol (2002) 1.06
Diagnosis and management of Wilson's disease: results of a single center experience. J Clin Gastroenterol (2006) 1.06
Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol (2008) 1.05
Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J Hepatol (2013) 1.04
Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol (2005) 1.04
Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology (2008) 1.03
Nutritional status at diagnosis is related to clinical outcomes in children and adolescents with cancer: a perspective from Central America. Eur J Cancer (2011) 1.03
Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol (2005) 1.02
Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol (2010) 1.02
Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood (2009) 1.01